by @dministrator | Mar 28, 2022 | NevakarInjectables
Bridgewater, NJ, USA, March 28, 2022 – Nevakar Injectables Inc., a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings, announced today the launch of its ready-to-use Ephedrine Sulfate...
by @dministrator | Mar 9, 2022 | NevakarInjectables
Bridgewater, NJ, USA, March 9, 2022 – Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it has closed on $12 million in convertible notes with both existing and new investors....
by @dministrator | May 25, 2021 | NevakarInjectables
Bridgewater, NJ (May 25, 2021) – Nevakar Inc. (“Nevakar”), a privately held biopharmaceutical company, today announces the establishment of Nevakar Injectables Inc., a newly formed company with an established portfolio of products focused on critical patient care,...
by @dministrator | Mar 1, 2021 | NevakarInjectables
By JASON J. NICHOLS, OD, MPH, PHD View the article | CLICK HERE Dr. Puri, please tell us about your company in terms of its history and direction…
by @dministrator | Oct 22, 2020 | NevakarInjectables
Bridgewater, NJ, October 22, 2020 – Nevakar Inc., a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today it received approval from the U.S. Food and Drug Administration (FDA) to market Ephedrine Sulfate Injection...
by @dministrator | Aug 24, 2020 | NevakarInjectables
December 8, 2019 – December 12, 2019
Recent Comments